Decreased Renal Gluconeogenesis Is a Hallmark of Chronic Kidney Disease. Issue 4 (April 2022)

• Record Type: Journal Article
• Authors: Verissimo, Thomas; Faivre, Anna; Rinaldi, Anna; Lindenmeyer, Maja; Delitsikou, Vasiliki; Veyrat-Durebex, Christelle; Heckenmeyer, Carolyn; Fernandez, Marylise; Berchtold, Lena; Dalga, Delal; Cohen, Clemens; Naesens, Maarten; Ricksten, Sven-Erik; Martin, Pierre-Yves; Pugin, Jérôme; Merlier, Franck; Haupt, Karsten; Rutkowski, Joseph M.; Moll, Solange; Cippà, Pietro E.; Legouis, David; de Seigneux, Sophie
• Is Part Of: Journal of the American Society of Nephrology. Volume 33:Issue 4(2022)
• Page Start: 810
• Page End: 827
• Publication Date: 2022-04
• Subjects: chronic kidney disease -- metabolism -- gluconeogenesis
• DOI: 10.1681/ASN.2021050680
• Languages: English
• ISSNs: 1046-6673

Abstract

Significance Statement: The ability to produce glucose from nonhexose precursors is a main metabolic function of renal proximal tubule (PT) cells. PT cells adapt metabolically during CKD, but little is known about gluconeogenesis in chronically injured PT cells. Our study demonstrates the progressive loss of gluconeogenesis enzymes in animal models and in CKD patients in parallel to global change in metabolic pathway expression and activation of injury pathways. This alteration is not only due to loss of PT cells but has systemic repercussions on glucose and lactate levels in experimental and human CKD. In retrospective human studies, gluconeogenesis downregulation predicted CKD progression. This work provides new evidence for metabolic regulation during CKD and the functional effect. Visual Abstract: Abstract : Introduction: CKD is associated with alterations of tubular function. Renal gluconeogenesis is responsible for 40% of systemic gluconeogenesis during fasting, but how and why CKD affects this process and the repercussions of such regulation are unknown. Methods: We used data on the renal gluconeogenic pathway from more than 200 renal biopsies performed on CKD patients and from 43 kidney allograft patients, and studied three mouse models, of proteinuric CKD (POD-ATTAC), of ischemic CKD, and of unilateral urinary tract obstruction. We analyzed a cohort of patients who benefitted from renal catheterization and a retrospective cohort of patients hospitalized in the intensive care unit. Results: Renal biopsies of CKD and kidney allograft patients revealed a stage-dependent decrease in the renal gluconeogenic pathway. Two animal models of CKD and one model of kidney fibrosis confirm gluconeogenic downregulation in injured proximal tubule cells. This shift resulted in an alteration of renal glucose production and lactate clearance during an exogenous lactate load. The isolated perfused kidney technique in animal models and renal venous catheterization in CKD patients confirmed decreased renal glucose production and lactate clearance. In CKD patients hospitalized in the intensive care unit, systemic alterations of glucose and lactate levels were more prevalent and associated with increased mortality and a worse renal prognosis at follow-up. Decreased expression of the gluconeogenesis pathway and its regulators predicted faster histologic progression of kidney disease in kidney allograft biopsies. Conclusion: Renal gluconeogenic function is impaired in CKD. Altered renal gluconeogenesis leads to systemic metabolic changes with a decrease in glucose and increase in lactate level, and is associated with a worse renal prognosis.